Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 3845
Gene Symbol: KRAS
KRAS
0.590 Biomarker disease BEFREE Some somatic oncogene mutations (BRAF, NRAS, HRAS, KRAS) as well as gene translocations (RET/PTC, PAX8/PPAR-gamma) have been associated with the development of thyroid cancer. 26259532 2016
Entrez Id: 3845
Gene Symbol: KRAS
KRAS
0.590 GeneticVariation disease BEFREE Diagnostically, KRAS mutation testing is useful in the workup of pancreaticobiliary and thyroid cancers, particularly using cytological specimens. 25487540 2015
Entrez Id: 3845
Gene Symbol: KRAS
KRAS
0.590 Biomarker disease BEFREE Mutations in BRAF, NRAS, KRAS and PTEN, that are known to be involved in thyroid cancer biology, were detected in seven FNA samples. 24834793 2015
Entrez Id: 3845
Gene Symbol: KRAS
KRAS
0.590 GeneticVariation disease BEFREE KRAS(S65N) was identified for the first time in thyroid cancer and could activate mitogen-associated protein kinase (MAPK). 24798740 2014
Entrez Id: 3845
Gene Symbol: KRAS
KRAS
0.590 GeneticVariation disease BEFREE Despite KRAS being the 6th most frequently mutated gene for all cancers, the reported frequency in thyroid cancer is only 2%. 22930660 2014
Entrez Id: 3845
Gene Symbol: KRAS
KRAS
0.590 GeneticVariation disease BEFREE Fourteen FNMTCs in patients from seven families were analyzed in terms of involvement of the four susceptibility loci, and 63 thyroid cancer tumors [FNMTC (29) and NMTC (34)] were evaluated for the occurrence of mutations in BRAF, and H-, N-, and K-RAS, using polymerase chain reaction, single-strand conformation polymorphism (PCR-SSCP) analysis, and direct sequencing. 21826673 2012
Entrez Id: 3845
Gene Symbol: KRAS
KRAS
0.590 GeneticVariation disease BEFREE The effect of activating somatic mutations in the KRAS and BRAF genes on the responsiveness to sunitinib was evaluated in a panel of thyroid cancer cell lines harboring wild-type KRAS and BRAF genes, the RET/PTC1 rearrangement, the G12R KRAS, or the V600E BRAF mutation. 22442268 2012
Entrez Id: 3845
Gene Symbol: KRAS
KRAS
0.590 GeneticVariation disease BEFREE We examined the activity of PLX4032 and PLX4720 in thyroid carcinoma cell lines harboring BRAF V600E (8505C, BCPAP, SW1736, BHT101), NRAS Q61R (HTH7), KRAS G12R (CAL62), HRAS G13R (C643), or RET/PTC1 (TPC-1) oncogenes. 19880792 2010
Entrez Id: 3845
Gene Symbol: KRAS
KRAS
0.590 Biomarker disease BEFREE We conclude that wild-type K-Ras.GTP in association with Gal-3 contributes to thyroid carcinoma malignancy and that Ras inhibition might be a useful treatment strategy against these deadly tumors. 20682656 2010
Entrez Id: 3845
Gene Symbol: KRAS
KRAS
0.590 Biomarker disease CTD_human Agent-specific ras oncogene activation in rat thyroid tumours. 3078959 1988
Entrez Id: 3845
Gene Symbol: KRAS
KRAS
0.590 CausalMutation disease CGI